Abstract | INTRODUCTION: METHODS: Univariate analyses and multivariate linear regression analyses assessed risk for radiographic progression (change in modified total Sharp score, DeltamTSS>0.5) from baseline to week 24 for C-reactive protein (CRP) and other baseline variables, and for 24-week time-averaged CRP (univariate analysis only). Subanalyses determined mean DeltamTSS for CRP subgroups. Analyses were post hoc, with observed data. RESULTS: One hundred and forty-four adalimumab-treated patients and 152 placebo-treated patients were assessed. Mean CRP was 64% lower by week 2 with adalimumab and essentially unchanged with placebo. Univariate analyses indicated that elevated CRP at baseline and time-averaged CRP were strongly associated with radiographic progression for placebo-treated patients but not for adalimumab-treated patients. Multivariate analysis confirmed that elevated baseline CRP was the only strong independent risk factor for radiographic progression (for CRP>or=1.0 mg/dl: odds ratio=3.28, 95% confidence interval=1.66 to 6.51, P<0.001). Adalimumab treatment reduced risk of progression approximately fivefold. The difference between mean DeltamTSS for adalimumab versus placebo was greatest for patients with baseline CRP>or=2.0 mg/dl (-0.5 vs. 2.6). CONCLUSIONS: Systemic inflammation in PsA, as indicated by elevated baseline CRP, was the only strong independent predictor of radiographic progression. This association was observed predominantly for placebo-treated patients. Adalimumab treatment substantially reduced the overall risk of radiographic progression, and provided greatest radiographic benefit for patients with the greatest CRP concentrations at baseline. TRIAL REGISTRATION: Trial registration: NCT00195689.
|
Authors | Dafna D Gladman, Philip J Mease, Ernest H S Choy, Christopher T Ritchlin, Renee J Perdok, Eric H Sasso |
Journal | Arthritis research & therapy
(Arthritis Res Ther)
Vol. 12
Issue 3
Pg. R113
( 2010)
ISSN: 1478-6362 [Electronic] England |
PMID | 20537151
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- C-Reactive Protein
- Adalimumab
|
Topics |
- Adalimumab
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Psoriatic
(diagnostic imaging, drug therapy, metabolism)
- C-Reactive Protein
(metabolism)
- Disease Progression
- Double-Blind Method
- Female
- Humans
- Linear Models
- Male
- Middle Aged
- Multivariate Analysis
- Radiography
- Risk Factors
- Treatment Outcome
|